Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310796 | 0.98 | ALOX5AP (0.47) | ALOX5APFEN1EPHX2GPR119HRH3 | |
| SCHEMBL4310792 | 0.98 | ALOX5AP (0.47) | ALOX5APFEN1EPHX2GPR119HRH3 | |
| SCHEMBL4321825 | 0.88 | CHEK2 (0.56) | EPHX2GPR119HRH3LIPECHEK2 | |
| SCHEMBL6535537 | 0.87 | GPR119 (0.49) | ALOX5APFEN1GPR119CHEK2 | |
| SCHEMBL2889380 | 0.87 | GPR119 (0.49) | ALOX5APFEN1GPR119CHEK2 | |
| SCHEMBL14045135 | 0.87 | GPR119 (0.49) | ALOX5APFEN1GPR119CHEK2 | |
| SCHEMBL4314692 | 0.87 | GPR119 (0.49) | ALOX5APFEN1GPR119CHEK2 | |
| SCHEMBL4326309 | 0.87 | GPR119 (0.49) | ALOX5APFEN1GPR119CHEK2 | |
| SCHEMBL6535548 | 0.87 | GPR119 (0.49) | ALOX5APFEN1GPR119CHEK2 | |
| SCHEMBL6535308 | 0.87 | GPR119 (0.49) | ALOX5APFEN1GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALOX5AP 4258/4885FEN1 3996/4885EPHX2 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.